Section Arrow
CUE.NASDAQ
- Cue Biopharma
Quotes are at least 15-min delayed:2024/05/15 13:36 EDT
Last
 1.59
+0.04 (+2.58%)
Day High 
1.665 
Prev. Close
1.55 
1-M High
2.26 
Volume 
130.14K 
Bid
1.58
Ask
1.6
Day Low
1.52 
Open
1.65 
1-M Low
1.3027 
Market Cap 
75.40M 
Currency USD 
P/E -- 
%Yield
10-SMA 1.89 
20-SMA 1.71 
50-SMA 1.81 
52-W High 4.89 
52-W Low 1.3027 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.07/-0.77
Enterprise Value
82.76M
Balance Sheet
Book Value Per Share
0.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.49M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8063-0.0565-6.55%-- 
NVAXNovavax12.66-0.82-6.08%-- 
JAGXJaguar Health0.259-0.0159-5.78%-- 
ARQTArcutis Biotherapeutics9.44+1.31+16.11%-- 
OCGNOcugen1.885+0.185+10.88%-- 
Quotes are at least 15-min delayed:2024/05/15 13:36 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.